<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 7, 1997
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
NEW JERSEY 1-1-432 22-2429994
- --------------------- ---------------- ---------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
- 2 -
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation announced that it has completed
the purchase of a pharmaceutical manufacturing facility from Searle Canada, a
unit of Monsanto Company. In addition to existing manufacturing and
packaging operations, the 100,852 square foot facility includes warehouse,
administrative, and QC/QA laboratory space. The facility, located in
Oakville Ontario, is approved by both the U.S. Food and Drug Administration
and the Health Protection Branch of Canada.
Roberts has historically outsourced all its manufacturing and packaging
functions. The Company anticipates several benefits with the purchase of
the Oakville facility, which will include substantial cost savings
through reduced cost of goods; lower inventory levels and greater flexibility
to match product supply with demand; and the integration of Roberts
Pharmaceutical Canada from leased space in Mississauga, Ontario to the
Oakville site.
Plans have been initiated to effect transfer of production of certain
over-the-counter products from third party manufacturers to Oakville in the
second half of 1997. This will be followed by a phase-in of the Company's
Canadian, U.K. and U.S. prescription products. Also, Searle has agreed to
lease back space from Roberts for a time. Roberts and Searle have agreed in
principle for Roberts to fulfill certain of Searle's packaging and clinical
supply requirements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: July 9, 1997 By: /s/ Anthony A. Rascio
----------------------------------
Anthony A. Rascio
Vice President
